Study S000307

A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01288326
Acronym: ROOTS
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 254
Start: 2011-02
Primary completion: 2013-03
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1116-2199

Registered primary outcomes

Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1% [month 12]
Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1% [month 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022844	ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Buysschaert M, Diabetes & metabolic syndrome	2015	Nonrandomized study	PMID 26004030 DOI	registry reference RESULT:26004030